-
公开(公告)号:ES2182064T3
公开(公告)日:2003-03-01
申请号:ES97919344
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , MARTINEZ-JIMENEZ PEDRO , FERNANDEZ-GADEA FRANCISCO , SIPIDO VICTOR KAREL
IPC: A61K31/00 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61P1/00 , A61P9/00 , A61P9/12 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D237/30 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/14 , C07D498/16
Abstract: PCT No. PCT/EP97/01830 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/39001 PCT Pub. Date Oct. 23, 1997This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero to 6; p is zero to 3; q is zero to 3; r is zero to 3; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, trihalomethyl, trihalomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or trihalomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; each independently represents a bivalent aromatic heterocycle wherein the heterocycle may be selected from the group consisting of pyrrole, pyrrazole, imidazole, triazole, furane, thiophene, isoxazole, oxazole, isothiazole, thiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine; or one of the two bivalent aromatic heterocycles in the compounds of formula (I) may be 1,2-benzenediyl; and aryl is optionally substituted phenyl; it further relates to compositions comprising thesae compounds, as well as their use as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:NO20026219A
公开(公告)日:2003-02-17
申请号:NO20026219
申请日:2002-12-23
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: EMELEN KRISTOF VAN , BRUYN MARCEL FRANS LEOPOLD DE , ALCAZAR-VACA MANUEL JESUS , ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , MATESANZ-BALLESTEROS MARIA ENC , BARTOLOME-NEBREDA JOSE MANUEL
IPC: C07D491/056 , A61K31/435 , A61K31/436 , A61K31/4545 , A61K31/513 , A61K31/5383 , A61P1/00 , A61P1/14 , C07D411/04 , C07D491/04 , C07D491/052 , C07D491/06 , C07D497/04 , C07D498/04
CPC classification number: C07D411/04 , C07D491/04
-
公开(公告)号:DK0892804T3
公开(公告)日:2002-12-02
申请号:DK97919344
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , MARTINEZ-JIMENEZ PEDRO , FERNANDEZ-GADEA FRANCISCO , SIPIDO VICTOR KAREL
IPC: A61K31/00 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61P1/00 , A61P9/00 , A61P9/12 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D237/30 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/14 , C07D498/16
Abstract: PCT No. PCT/EP97/01830 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/39001 PCT Pub. Date Oct. 23, 1997This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero to 6; p is zero to 3; q is zero to 3; r is zero to 3; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, trihalomethyl, trihalomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or trihalomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; each independently represents a bivalent aromatic heterocycle wherein the heterocycle may be selected from the group consisting of pyrrole, pyrrazole, imidazole, triazole, furane, thiophene, isoxazole, oxazole, isothiazole, thiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine; or one of the two bivalent aromatic heterocycles in the compounds of formula (I) may be 1,2-benzenediyl; and aryl is optionally substituted phenyl; it further relates to compositions comprising thesae compounds, as well as their use as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:HU221608B
公开(公告)日:2002-11-28
申请号:HU9901875
申请日:1997-04-09
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , MARTINEZ PEDRO , SIPIDO VICTOR KAREL
IPC: A61K31/00 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/553 , A61P1/00 , A61P9/00 , A61P9/12 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D237/30 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D498/14 , C07D498/16
Abstract: PCT No. PCT/EP97/01830 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/39001 PCT Pub. Date Oct. 23, 1997This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero to 6; p is zero to 3; q is zero to 3; r is zero to 3; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, trihalomethyl, trihalomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl or C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or trihalomethyl; X is CR6R7, NR8, O, S, S(=O) or S(=O)2; each independently represents a bivalent aromatic heterocycle wherein the heterocycle may be selected from the group consisting of pyrrole, pyrrazole, imidazole, triazole, furane, thiophene, isoxazole, oxazole, isothiazole, thiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine; or one of the two bivalent aromatic heterocycles in the compounds of formula (I) may be 1,2-benzenediyl; and aryl is optionally substituted phenyl; it further relates to compositions comprising thesae compounds, as well as their use as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:HU0003748A2
公开(公告)日:2002-01-28
申请号:HU0003748
申请日:1998-10-06
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , DIAZ-MARTINEZ ADOLFO , FERNANDEZ-GADEA FRANCISCO JAVI , GIL-LOPETEGUI PILAR
IPC: A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D401/06 , C07D405/06 , C07D493/04
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
公开(公告)号:GR3035680T3
公开(公告)日:2001-06-29
申请号:GR20010400530
申请日:2001-03-30
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: SIPIDO VICTOR KAREL , FERNANDEZ-GADEA FRANCISCO JAVI , ANDRES-GIL JOSE IGNACIO , MEERT THEO FRANS , GIL-LOPETEGUI PILAR
IPC: A61K31/535 , A61K31/55 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , C07D223/20 , C07D223/30 , C07D261/00 , C07D498/04
Abstract: This invention concerns the compounds of formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the N-oxide forms thereof. (I) wherein: R1 and R2 each independently are hydrogen; C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R3, R4, R5, R6, R9, R10, R11 or R12 each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)-amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxy-carbonyl; R7 and R8 are each independently hydrogen, hydroxy, C1-6alkyl, C1-6alkyloxy or R7 and R8 taken together may form mono- or di(cyano)methylene, or together with the carbon atom to which they are attached form a carbonyl or a spiro substituent; or R7 and R8 taken together may form methylene; R13 is hydrogen, C1-6alkyl, or trifluoromethyl; R14 is hydrogen, C1-6alkyl, cyano, or trifluoromethyl; n is zero to 6. These compounds were tested as mCPP-antagonists in rats. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
公开(公告)号:RO116729B1
公开(公告)日:2001-05-30
申请号:RO9600283
申请日:1994-08-12
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: VAN LOMMEN GUY ROSALIA EUGENE , FERNANDEZ-GADEA FRANCISCO JAVIER , ANDRES-GIL JOSE IGNACIO , MATESANZ-BALLESTEROS MARIA ENCARNACION
IPC: A61K31/35 , A61K31/436 , A61K31/44 , A61K31/453 , A61K31/505 , A61P9/02 , A61P9/08 , A61P25/04 , A61P25/06 , C07D405/12 , C07D491/04 , C07D491/052
Abstract: Invenţia se referă la derivaţi de dihidropiranopiridine cu formula (I):în care = a=a=a=aeste un radical bivalent cu formula: =N-CH=CH-CH= (a) =CH-N=CH-CH= (b) =CH-CH=N-CH= (c) =CH-CH=CH-N= (d) în care unul sau doi atomi de hidrogen, din radicalii bivalenţi, pot fi substituiţi cu halogen, hidroxi, Calchil sau Calchiloxi; Reste hidrogen sau Calchil; Reste hidrogen sau C; Reste hidrogen sau Calchil; Alkeste Calcandiil; Alkeste Calcandiil, la procedeele de preparare a acestor compuşi şi la un intermediar utilizat la obţinerea derivaţilor cu formula (i). Derivaţii de dihidropiranopiridine cu formula (I) sunt utilizaţi la tratarea bolilor caracterizate printr-o vasodilataţie excesivă, în special migrena, în tratamentul insuficienţei venoase şi a hipotensiunii.
-
公开(公告)号:EE200000161A
公开(公告)日:2001-04-16
申请号:EEP200000161
申请日:1998-10-06
Applicant: JANSSEN PHARMACEUTICA NV
IPC: A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D401/06 , C07D405/06 , C07D493/04
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
公开(公告)号:HK1029106A1
公开(公告)日:2001-03-23
申请号:HK00107164
申请日:2000-11-10
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: ANDRES-GIL JOSE IGNACIO , FERNANDEZ-GADEA FRANCISCO JAVI , GIL-LOPETEGUI PILAR , DIAZ-MARTINEZ ADOLFO
IPC: A61K31/34 , A61K31/343 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4525 , A61K31/495 , A61K31/496 , A61K31/535 , A61K31/5377 , A61K31/55 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/30 , C07D307/93 , C07D401/06 , C07D405/06 , C07D493/04 , C07D , A61K
Abstract: This invention concerns the compounds of formula (I),the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is zero, 1, 2, 3, 4, 5 or 6; X is CH2 or O; R and R each independently are hydrogen, C1-6alkyl, C1-6alkylcarbonyl, halomethylcarbonyl or C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R and R taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R and R are both halogen; or R is halogen and R is hydrogen; or R is hydrogen and R is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C1-6alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.
-
公开(公告)号:DE69520071D1
公开(公告)日:2001-03-15
申请号:DE69520071
申请日:1995-10-25
Applicant: JANSSEN PHARMACEUTICA NV
Inventor: FERNANDEZ-GADEA FRANCISCO JAVI , SIPIDO KAREL , ANDRES-GIL JOSE IGNACIO , MEERT FRANS
IPC: A61K31/535 , A61K31/55 , A61K31/553 , A61K31/554 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/26 , C07D261/20 , C07D267/16 , C07D498/04 , C07D513/04
Abstract: PCT No. PCT/EP95/04197 Sec. 371 Date Apr. 25, 1997 Sec. 102(e) Date Apr. 25, 1997 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/14321 PCT Pub. Date May 17, 1996This invention concerns the compounds of formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the N-oxide forms thereof. (I) wherein: R1 and R2 each independently are hydrogen; C1-6alkyl; C1-6alkylcarbonyl; trihalomethylcarbonyl; C1-6alkyl substituted with hydroxy, C1-6alkyloxy, carboxyl, C1-6alkylcarbonyloxy, C1-6alkyloxycarbonyl or aryl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R3 to R10 each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)-aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; R11 is hydrogen, C1-6alkyl, or trifluoromethyl; R12 is hydrogen, C1-6alkyl, cyano, or trifluoromethyl; n is zero to 6; and X is O, S, S(=O) or S(=O)2. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
-
-
-
-
-
-
-
-
-